NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
OGI
Organigram Global Inc.
OGI has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OGI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Healthy |
OGI's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OGI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.83 | — |
| Cheap | 8x | $3.58 | +331% |
| Fair | 14x | $6.30 | +659% |
| Expensive | 28x | $12.62 | +1421% |
Historical ranges are pointers, not guarantees.
OGI has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OGI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OGI has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OGI on earnings, with more consistent year-over-year improvement.
OGI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.45 | +$0.45 |
| Q1 2026 | -$0.13 | -360% |
| Q4 2025 | $0.10 | +$0.49 |
| Q3 2025 | -$0.15 | +$0.23 |
| Q2 2025 | -$0.00 | +$0.61 |
| Q2 2024 | -$0.61 | +$1.34 |
| Q2 2023 | -$1.95 | -$1.63 |
| Q1 2023 | -$0.10 | +$0.25 |
OGI has returned to profit: it earned $0.45 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OGI on profitability, with a higher operating margin.
OGI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $74.4M | +49% |
| Q1 2026 | $42M | -8.9% |
| Q4 2025 | $44.6M | +49% |
| Q3 2025 | $56.3M | +79% |
| Q2 2025 | $49.8M | +72% |
| Q1 2025 | $46.1M | +74% |
| Q4 2024 | $30M | +17% |
| Q3 2024 | $31.4M | -2.9% |
OGI's revenue is growing: $74M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5% | +8 points |
| Q1 2026 | -16% | -4.8 points |
| Q4 2025 | -5.4% | +11 points |
| Q3 2025 | 1.5% | +0.9 points |
| Q2 2025 | -3% | +9.3 points |
| Q1 2025 | -12% | +29 points |
| Q4 2024 | -16% | +28 points |
| Q3 2024 | 0.6% | +86 points |
OGI's operating margin was 5% last quarter, up 8 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OGI on cash generation, producing positive trailing cash flow while its opponent burns cash.
OGI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -177% |
| Q1 2026 | -$4.9M | +$11.3M |
| Q4 2025 | -$12.7M | -$8.6M |
| Q3 2025 | -$483.7K | -110% |
| Q2 2025 | $3.5M | +$6.9M |
| Q1 2025 | -$16.3M | -$9.4M |
| Q4 2024 | -$4.1M | -194% |
| Q3 2024 | $4.9M | +$21.3M |
OGI has burned cash in almost every quarter: −$21M over the past year, against −$12M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OGI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OGI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +5M shares |
| 1 year | +2% | +2.6M shares |
| 3 years | +71% | +56.6M shares |
| 5 years | +142% | +80.2M shares |
| Available history | +262% | +98.8M shares |
OGI has 137M diluted shares, up 2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OGI hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OGI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | -8.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -7.3x | Net Cash |
| Q2 2025 | -7.0x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
| Q4 2022 | -3.9x | Net Cash |
OGI's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OGI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 4.9 | Oversold |
OGI's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OGI PE vs Healthcare Sector
| Metric | OGI | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 0 | 29 | 29 pts below |
OGI has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over OGI on trend strength, trading above more of its moving averages.
OGI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 12% below |
| 20 week MA | $1.01 | 18% below |
| 50 week MA | $1.26 | 34% below |
| 100 week MA | $1.35 | 39% below |
| 200 week MA | $1.59 | 48% below |
OGI is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over OGI on returns for 2026, with the stronger performance.
OGI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.40 | $5.68 | -40% |
| 2021 | $5.68 | $8.00 | +41% |
| 2022 | $8.00 | $3.12 | -61% |
| 2023 | $3.12 | $1.31 | -58% |
| 2024 | $1.31 | $1.62 | +24% |
| 2025 | $1.62 | $1.79 | +10% |
| 2026 YTD | $1.79 | $0.83 | -54% |
OGI has finished lower in three of the last six years. It's down 54% so far in 2026.